Spyre Therapeutics financials
$84.72−1.25%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $886.0K |
| Gross profit | $0.00 | $0.00 | $886.0K |
| Gross margin | — | — | 100.0% |
| Operating income | -$219.6M | -$208.6M | -$258.8M |
| Net income | -$126.5M | -$149.6M | -$94.9M |
| Net margin | — | — | −10709.1% |
| Diluted EPS | $-1.98 | $-3.18 | $-13.76 |
| EBITDA | -$219.6M | -$208.6M | -$258.0M |
| Operating cash flow | -$169.3M | -$157.4M | -$99.9M |
| Free cash flow | -$169.3M | -$157.4M | -$99.9M |
| Diluted shares | 64.1M | 47.0M | 6.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $85.7M | $89.4M | $188.9M |
| Short-term investments | $670.8M | $513.7M | $150.4M |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $777.8M | $608.5M | $341.9M |
| Total liabilities | $62.5M | $90.7M | $73.3M |
| Shareholders' equity | $715.2M | $517.8M | $184.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology